文献速递泌尿生殖与妇科肿瘤放疗

中危前列腺癌治疗优化:随机III期试验二次分析

Optimizing Treatment in Intermediate-Risk Prostate Cancer: Secondary Analysis of a Randomized Phase 3 Trial.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2021-04-24

该研究对一项III期随机试验进行二次分析,按预后中危因素将中危前列腺癌患者分为有利中危(FIR)和不利中危(UIR)两组,比较不同治疗臂的生化失败、远处转移、前列腺癌特异性死亡、总生存和无远处转移生存。中位随访11.3年,结果显示FIR患者各治疗臂间生化失败和总生存无显著差异,而UIR患者接受ADT联合放疗较单用剂量递增放疗显著改善生化失败。

要点

  • FIR患者(仅1个中危因素且无Gleason 4+3或阳性穿刺针≥50%)各治疗臂生化失败和总生存无显著差异。
  • UIR患者接受ADT的臂较单用DERT76显著改善生化失败。
  • UIR患者无远处转移生存和总生存显著差于FIR患者。

核心结论

  • 在中危前列腺癌中,治疗优化是可能的:FIR患者单用DERT76似乎足以避免ADT副作用,而其他UIR患者似乎受益于ADT联合DERT76。

研究设计与样本

  • 对一项III期随机试验的二次分析,该试验将600例中危前列腺癌患者随机分为3臂(每臂200例):ADT+RT70、ADT+DERT76和单用DERT76。
  • 按预后中危因素(临床分期、PSA水平、Gleason评分、阳性穿刺针百分比≥50%和Gleason模式)将患者分为FIR和UIR两组。

主要发现

  • 中位随访11.3年(四分位距10.9-11.7)。
  • FIR队列中各臂间生化失败和总生存无显著差异。
  • UIR患者中,接受ADT的臂较单用DERT76显著改善生化失败。
  • 多变量分析显示,Gleason模式4+3和PSA>10 ng/mL独立影响生化失败和总生存, regardless of treatment arm。

关键数值与推荐

  • FIR定义:仅有1个中危因素且无Gleason模式4+3或阳性穿刺针≥50%。
  • UIR定义:所有其他患者。

临床怎么用

  • 对于FIR患者,可考虑单用剂量递增放疗(DERT76)以避免ADT副作用。
  • 对于UIR患者,ADT联合DERT76似乎带来生化失败获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To identify patients with intermediate-risk prostate cancer (IRPC) benefiting from de-escalation of androgen deprivation therapy (ADT) and/or dose escalated radiation therapy (DERT), we performed a secondary analysis of a phase 3 trial by measuring biochemical failure (BF), distant metastases, prostate cancer-specific mortality, overall survival (OS), and distant metastases-free survival (DMFS) rates according to prognostic intermediate risk factors (IRF). METHODS AND MATERIALS: The initial trial randomized 600 patients with IRPC to a 3-arm trial with 200 patients per arm, consisting of 6 months of ADT plus 70 Gy radiation therapy (ADT + RT70) versus ADT plus a DERT of 76 Gy (ADT + DERT76) versus DERT of 76 Gy alone (DERT76). We performed an analysis based on IRF: clinical stage, prostate-specific antigen level, Gleason score, percentage of positive biopsy cores (PBC) ≥50%, and Gleason pattern. Patients were allocated to 2 groups: favorable intermediate risk (FIR), defined as patients with only 1 IRF without Gleason pattern 4 + 3 or PBC ≥50%; and unfavorable intermediate risk (UIR), defined as all other patients. BF, distant metastases, prostate cancer-specific mortality, OS, and DMFS were compared between FIR and UIR. RESULTS: The median follow-up was 11.3 years (interquartile range, 10.9-11.7). In the FIR cohort, BF and OS were not significantly different between arms. UIR patients had significantly worse DMFS (hazard ratio [95% confidence interval], 1.61 [1.20-2.15]; P = .026) and OS (1.51 [1.12-2.04]; P = .0495) and a nonsignificant higher cumulative incidence of BF rate (1.55 [0.98-2.47]; P = .08). In UIR patients, a significant improvement in BF was seen in the arms receiving ADT compared to DERT76 alone. On multivariable analysis, Gleason pattern 4 + 3 and prostate-specific antigen >10 ng/mL independently affected BF and OS, regardless of the treatment arm. CONCLUSIONS: In IRPC, therapeutic optimization appears possible. To avoid ADT side effects, DERT76 alone appears sufficient in patients harboring only 1 risk factor without Gleason pattern 4 + 3 and PBC ≥50% (FIR). All other UIR patients seem to benefit from ADT + DERT76.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Nabid A, Carrier N, Vigneault E, et al. Optimizing Treatment in Intermediate-Risk Prostate Cancer: Secondary Analysis of a Randomized Phase 3 Trial. Int J Radiat Oncol Biol Phys. 2021. PMID: 33901566. doi:10.1016/j.ijrobp.2021.04.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。